Scholarlink

<p>Centromere-antibody-positive limited cutaneous systemic sclerosis (LCSSc) is a&#xa0;common disease. It generally takes a&#xa0;benign course, but can still considerably reduce quality of life. Our patient—a&#xa0;woman born in 1987 who was first diagnosis 2017—suffered from pain and declining hand function due to sclerodactyly and calcinosis. Methotrexate (MTX) and analgesics were not effective. After commencing off-label treatment with filgotinib, the patient reported rapid improvement. An&#xa0;X-ray after 8&#xa0;months showed a&#xa0;reduction in calcinosis load. Filgotinib is well tolerated. Sclerodactyly has resolved, and hand function continues to improve. The clinical and radiological response merit further enquiry of Janus kinase (JAK) inhibitors in centromere-antibody-positive LCSSc.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Filgotinib gegen Kalzinose bei Zentromer-Antikörper-positiver systemischer Sklerose

  • 期刊论文

  • 发表日期：

    2026年2月2日

查看全文
  • Ottar Gadeholt

摘要

Centromere-antibody-positive limited cutaneous systemic sclerosis (LCSSc) is a common disease. It generally takes a benign course, but can still considerably reduce quality of life. Our patient—a woman born in 1987 who was first diagnosis 2017—suffered from pain and declining hand function due to sclerodactyly and calcinosis. Methotrexate (MTX) and analgesics were not effective. After commencing off-label treatment with filgotinib, the patient reported rapid improvement. An X-ray after 8 months showed a reduction in calcinosis load. Filgotinib is well tolerated. Sclerodactyly has resolved, and hand function continues to improve. The clinical and radiological response merit further enquiry of Janus kinase (JAK) inhibitors in centromere-antibody-positive LCSSc.